ATAI Life Sciences N.V (NASDAQ:ATAI) has a beta value of 1.22 and has seen 1.26 million shares traded in the last trading session. The company, currently valued at $287.70M, closed the last trade at $1.44 per share which meant it gained $0.05 on the day or 3.60% during that session. The ATAI stock price is -78.47% off its 52-week high price of $2.57 and 28.47% above the 52-week low of $1.03.
The consensus among analysts is that ATAI Life Sciences N.V (ATAI) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Sporting 3.60% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ATAI stock price touched $1.44 or saw a rise of 3.03%. Year-to-date, ATAI Life Sciences N.V shares have moved 8.27%, while the 5-day performance has seen it change -2.04%. Over the past 30 days, the shares of ATAI Life Sciences N.V (NASDAQ:ATAI) have changed 19.01%.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 76.0% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -316.67% off the targeted high while a plunge would see the stock gain -316.67% from current levels.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
The company’s shares have gained 22.03% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 18.62% over the past 5 years. Earnings growth for 2025 is a modest 23.00% while over the next 5 years, the company’s earnings are expected to increase by 17.72%.
ATAI Dividends
ATAI Life Sciences N.V is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
The top two institutional holders are WALLEYE CAPITAL LLC with over 2.76 million shares worth more than $3.67 million. As of 2024-06-30, WALLEYE CAPITAL LLC held 1.7226% of shares outstanding.
The other major institutional holder is MORGAN STANLEY, with the holding of over 2.72 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.62 million and represent 1.6952% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are MORGAN STANLEY INSTITUTIONAL FUND INC-Inception Portfolio and AdvisorShares Trust-AdvisorShares Psychedelics ETF . As of Dec 31, 2024 , the former fund manager holds about 0.26% shares in the company for having 511.99 shares of worth $0.74 million while later fund manager owns 408.76 shares of worth $0.59 million as of Mar 31, 2025 , which makes it owner of about 0.20% of company’s outstanding stock.
